Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors

References

• PeggsKSQuezadaSAChambersCAKormanAJAllisonJPBlockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodiesJ Exp Med20092061717172519581407
   PubMed Web of Science ®Google Scholar
• ShrikantPKhorutsAMescherMFCTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanismImmunity19991148349310549630
   PubMed Web of Science ®Google Scholar
• KeirMEButteMJFreemanGJSharpeAHPD-1 and its ligands in tolerance and immunityAnnu Rev Immunol20082667770418173375
   PubMed Web of Science ®Google Scholar
• MellmanICoukosGDranoffGCancer immunotherapy comes of ageNature201148048048922193102
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med201036371172320525992
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarba-zine for previously untreated metastatic melanomaN Engl J Med20113642517252621639810
   PubMed Web of Science ®Google Scholar
• RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med201537232033025399552
   PubMed Web of Science ®Google Scholar
• RobertCRibasAWolchokJDAnti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialLancet20143841109111725034862
   PubMed Web of Science ®Google Scholar
• WeberJSD’AngeloSPMinorDNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialLancet Oncol20151637538425795410
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med20153731627163926412456
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med201537312313526028407
   PubMed Web of Science ®Google Scholar
• HerbstRSBaasPKimDWPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet20163871540155026712084
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBMcDermottDFCheckMate, nivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med201557318031813
   Google Scholar
• ChowLQHaddadRGuptaSSeiwert, antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 Expansion CohortJ Clin Oncol2016343838384527646946
   PubMed Web of Science ®Google Scholar
• FerrisRLBlumenscheinGJrFayetteJGillison, nivolumab for recurrent squamous-cell carcinoma of the head and neckN Engl J Med20163751856186727718784
   PubMed Web of Science ®Google Scholar
• ApoloABInfanteJRBalmanoukianAAvelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib studyJ Clin Oncol2017352117212428375787
   PubMed Web of Science ®Google Scholar
• MassardCGordonMSSharmaSSegal, safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancerJ Clin Oncol2016343119312527269937
   PubMed Web of Science ®Google Scholar
• AnsellSMLesokhinAMBorrelloIArmand, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphomaN Engl J Med201537231131925482239
   PubMed Web of Science ®Google Scholar
• LawrenceMSStojanovPPolakPMutational heterogeneity in cancer and the search for new cancer-associated genesNature201349921421823770567
   PubMed Web of Science ®Google Scholar
• ChampiatSDercleLAmmariSHyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1Clin Cancer Res2017231920192827827313
   PubMed Web of Science ®Google Scholar
• FDA alerts healthcare professionals and oncology clinical investigators about two clinical trials on hold evaluating KEYTRUDA® (pembroli-zumab) in patients with multiple myeloma Available from: https://www.fda.gov/Drugs/DrugSafety/ucm574305.htmAccessed April 1, 2018
   Google Scholar
• PatelSPKurzrockRPD-L1 expression as a predictive biomarker in cancer immunotherapyMol Cancer Ther20151484785625695955
   PubMed Web of Science ®Google Scholar
• Pembrolizumab (KEYTRUDA) Checkpoint Inhibitor Available from: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm526430.htm
   Google Scholar
• RittmeyerABarlesiFWaterkampDO.A.K.S. GroupAtezoli-zumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialLancet201738925526527979383
   PubMed Web of Science ®Google Scholar
• FehrenbacherLSpiraABallingerMP.S. GroupAtezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLancet20163871837184626970723
   PubMed Web of Science ®Google Scholar
• Giroux LeprieurEDumenilCJulieCImmunotherapy revolutionises non-small-cell lung cancer therapy: results, perspectives and new challengesEur J Cancer201778162328407528
   PubMed Web of Science ®Google Scholar
• CarboneDPReckMPaz-AresLCheckMate, first-line nivolumab in stage IV or recurrent non-small-cell lung cancerN Engl J Med20173762415242628636851
   PubMed Web of Science ®Google Scholar
• ReckMRodriguez-AbreuDRobinsonAGPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancerN Engl J Med20163751823183327718847
   PubMed Web of Science ®Google Scholar
• KeeDMcArthurGImmunotherapy of melanomaEur J Surg Oncol20174359460327514721
   PubMed Web of Science ®Google Scholar
• BalarAVGalskyMDRosenbergJEI.M.S. GroupAtezoli-zumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialLancet2017389677627939400
   PubMed Web of Science ®Google Scholar
• SharmaPCallahanMKBonoPRosenberg, Nivolumab mono-therapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trialLancet Oncol2016171590159827733243
   PubMed Web of Science ®Google Scholar
• ChaeYKPanADavisAABiomarkers for PD-1/PD-L1 blockade therapy in non-small-cell lung cancer: is PD-L1 expression a good marker for patient selection?Clin Lung Cancer20161735036127137346
   PubMed Web of Science ®Google Scholar
• HansenARSiuLLPD-L1 testing in cancer: challenges in companion diagnostic developmentJAMA Oncol20162151626562503
   PubMed Web of Science ®Google Scholar
• MengXHuangZTengFXingLYuJPredictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapyCancer Treat Rev20154186887626589760
   PubMed Web of Science ®Google Scholar
• InoueYYoshimuraKMoriKSugimura, Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancerOncotarget20167321133212827050074
   PubMed Web of Science ®Google Scholar
• MukherjiDJabbourMNSaroufimMProgrammed death-ligand 1 expression in muscle-invasive bladder cancer cystectomy specimens and lymph node metastasis: a reliable treatment selection biomarker?Clin Genitourin Cancer20161418318726775720
   PubMed Web of Science ®Google Scholar
• CalleaMAlbigesLGuptaMDifferential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinomaCancer Immunol Res201531158116426014095
   PubMed Web of Science ®Google Scholar
• MadoreJVilainREMenziesAMPD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trialsPigment Cell Melanoma Res20152824525325477049
   PubMed Web of Science ®Google Scholar
• HerbstRSSoriaJCKowanetzMPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature201451556356725428504
   PubMed Web of Science ®Google Scholar
• Van AllenEMMiaoDSchillingBGenomic correlates of response to CTLA-4 blockade in metastatic melanomaScience201535020721126359337
   PubMed Web of Science ®Google Scholar
• YearleyJHGibsonCYuNPD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancerClin Cancer Res2017233158316728619999
   PubMed Web of Science ®Google Scholar
• ChenDSMellmanIElements of cancer immunity and the cancer-immune set pointNature201754132133028102259
   PubMed Web of Science ®Google Scholar
• TaylorNAVickSCIglesiaMDTreg depletion potentiates checkpoint inhibition in claudin-low breast cancerJ Clin Invest20171273472348328825599
   PubMed Web of Science ®Google Scholar
• PageDBYuanJRedmondDDeep sequencing of T-cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapyCancer Immunol Res2016483584427587469
   PubMed Web of Science ®Google Scholar
• DaudAILooKPauliMLTumor immune profiling predicts response to anti-PD-1 therapy in human melanomaJ Clin Invest20161263447345227525433
   PubMed Web of Science ®Google Scholar
• LinesJLPantaziEMakJVISTA is an immune checkpoint molecule for human T cellsCancer Res2014741924193224691993
   PubMed Web of Science ®Google Scholar
• TakeuchiYNishikawaHRoles of regulatory T cells in cancer immunityInt Immunol20162840140927160722
   PubMed Web of Science ®Google Scholar
• LiXShaoCShiYHanWLessons learned from the blockade of immune checkpoints in cancer immunotherapyJ Hematol Oncol2018113129482595
   PubMed Web of Science ®Google Scholar
• LowtherDEGoodsBALuccaLEPD-1 marks dysfunctional regulatory T cells in malignant gliomasJCI Insight20161e8593527182555
   PubMed Web of Science ®Google Scholar
• HamidOSchmidtHNissanAA prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaJ Transl Med2011920422123319
   PubMed Web of Science ®Google Scholar
• SelbyMJEngelhardtJJQuigleyMAnti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cellsCancer Immunol Res20131324224777248
   PubMed Web of Science ®Google Scholar
• SimpsonTRLiFMontalvo-OrtizWFc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanomaJ Exp Med20132101695171023897981
   PubMed Web of Science ®Google Scholar
• CoussensLMWerbZInflammation and cancerNature200242086086712490959
   PubMed Web of Science ®Google Scholar
• PardollDMThe blockade of immune checkpoints in cancer immu-notherapyNat Rev Cancer20121225226422437870
   PubMed Web of Science ®Google Scholar
• RemonJChaputNPlanchardDPredictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancerCurr Opin Oncol20162812212926756384
   PubMed Web of Science ®Google Scholar
• ParkerBSRautelaJHertzogPJAntitumour actions of interferons: implications for cancer therapyNat Rev Cancer20161613114426911188
   PubMed Web of Science ®Google Scholar
• RibasAHodiFWolchokJResponse to PD-1 blockade with pembrolizumab (MK-3475) is Associated with an interferon inflammatory immune gene signatureASCO Annual MeetingMay 29–June 2, 2015Chicago, Illinois
   Google Scholar
• BenciJLXuBQiuYTumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockadeCell201616715401554 e151227912061
   PubMed Web of Science ®Google Scholar
• ZaretskyJMGarcia-DiazAShinDSMutations associated with acquired resistance to PD-1 blockade in melanomaN Engl J Med201637581982927433843
   PubMed Web of Science ®Google Scholar
• GaoJShiLZZhaoHLoss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapyCell2016167397404.e39927667683
   PubMed Web of Science ®Google Scholar
• KowanetzMShamesDSCummingsCTumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLCAnn Oncol20162777P
   Web of Science ®Google Scholar
• GoodmanAMKatoSBazhenovaLTumor mutational burden as an independent predictor of response to immunotherapy in diverse cancersMol Cancer Ther2017162598260828835386
   PubMed Web of Science ®Google Scholar
• YaghmourGPandeyMIrelandCRole of genomic instability in immunotherapy with checkpoint inhibitorsAnticancer Res20162640334038
   Google Scholar
• JohnsonDBFramptonGMRiothMJTargeted next generation sequencing identifies markers of response to PD-1 BlockadeCancer Immunol Res2016495996727671167
   PubMed Web of Science ®Google Scholar
• RizviNAHellmannMDSnyderACancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerScience201534812412825765070
   PubMed Web of Science ®Google Scholar
• CampesatoLFBarroso-SousaRJimenezLComprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practiceOncotarget20156342213422726439694
   PubMedGoogle Scholar
• HellmannMDCiuleanuTEPluzanskiANivolumab plus Ipi-limumab in lung cancer with a high tumor mutational burdenN Engl J Med Epub2018416
   Web of Science ®Google Scholar
• RosenbergJEHoffman-CensitsJPowlesTAtezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialLancet20163871909192026952546
   PubMed Web of Science ®Google Scholar
• BellmuntJde WitRVaughnDJPembrolizumab as second-line therapy for advanced urothelial carcinomaN Engl J Med20173761015102628212060
   PubMed Web of Science ®Google Scholar
• GettingerSNHornLGandhiLOverall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancerJ Clin Oncol2015332004201225897158
   PubMed Web of Science ®Google Scholar
• BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med20123662455246522658128
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSznol, safety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med20123662443245422658127
   PubMed Web of Science ®Google Scholar
• SchumacherTNSchreiberRDNeoantigens in cancer immunotherapyScience2015348697425838375
   PubMed Web of Science ®Google Scholar
• McGranahanNFurnessAJRosenthalRClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockadeScience20163511463146926940869
   PubMed Web of Science ®Google Scholar
• LeDTDurhamJNSmithKNMismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience201735740941328596308
   PubMed Web of Science ®Google Scholar
• FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication Available from: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm560040.htmAccessed April 1, 2018
   Google Scholar
• IyerRRPluciennikABurdettVModrichPLDNA mismatch repair: functions and mechanismsChem Rev200610630232316464007
   PubMed Web of Science ®Google Scholar
• SmyrkTCWatsonPKaulKLynchHTTumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinomaCancer2001912417242211413533
   PubMed Web of Science ®Google Scholar
• HowittBEShuklaSAShollLMAssociation of polymerase e-mutated and microsatellite-instable endometrial cancers with neoan-tigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1JAMA Oncol201511319132326181000
   PubMed Web of Science ®Google Scholar
• ChenKHYuanCTTsengLHShunCTYehKHCase report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistanceJ Hematol Oncol201692927012666
   PubMed Web of Science ®Google Scholar
• Lyford-PikeSPengSYoungGDEvidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinomaCancer Res2013731733174123288508
   PubMed Web of Science ®Google Scholar
• QinYEkmekciogluSForgetMACervical cancer neoantigen landscape and immune activity is associated with human papilloma-virus master regulatorsFront Immunol2017868928670312
   PubMed Web of Science ®Google Scholar
• FrenelJSLe TourneauCO’NeilBVarga, safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trialJ Clin Oncol2017354035404129095678
   PubMed Web of Science ®Google Scholar
• PartlovaSBoucekJKloudovaKDistinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinomaOncoimmunology20154e96557025949860
   PubMed Web of Science ®Google Scholar
• MezacheLPanicciaBNyinawaberaANuovoGJEnhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancersMod Pathol2015281594160226403783
   PubMed Web of Science ®Google Scholar
• DerksSLiaoXChiaravalliAMAbundant PD-L1 expression in Epstein-Barr virus-infected gastric cancersOncotarget20167329253293227147580
   PubMed Web of Science ®Google Scholar
• MaCPatelKSinghiADProgrammed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated with Epstein-Barr Virus or Microsatellite InstabilityAm J Surg Pathol2016401496150627465786
   PubMed Web of Science ®Google Scholar
• RooneyMSShuklaSAWuCJGetzGHacohenNMolecular and genetic properties of tumors associated with local immune cytolytic activityCell2015160486125594174
   PubMed Web of Science ®Google Scholar
• SeiwertTYBurtnessBMehraRSafety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialLancet Oncol20161795696527247226
   PubMed Web of Science ®Google Scholar
• HollebecqueAMeyerTMooreKNAn open-label, multicohort, phase 1/2 study of nivolumab in patients with virus-associated tumors (CheckMate 358): efficacy and safety in recurrent or metastatic cervical, vaginal, and vulvar cancersPresented at American Society of Clinical Oncology Annual MeetingJune 2–6, 2017Chicago, IL Abstract 5504
   Google Scholar
• GainorJFShawATSequistLVEGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysisClin Cancer Res2016224585459327225694
   PubMed Web of Science ®Google Scholar
• HarataniKHayashiHTanakaTTumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatmentAnn Oncol2017281532153928407039
   PubMed Web of Science ®Google Scholar
• TabchiSKourieHRKattanJAdding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategyInvest New Drugs20163479479627562868
   PubMed Web of Science ®Google Scholar
• OvermanMJMcDermottRLeachJLNivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyLancet Oncol2017181182119128734759
   PubMed Web of Science ®Google Scholar
• BradleySDChenZMelendezBBRAFV600E co-opts a conserved MHC class I internalization pathway to diminish antigen presentation and CD8+ T-cell recognition of melanomaCancer Immunol Res2015360260925795007
   PubMed Web of Science ®Google Scholar
• AtkinsDBreuckmannASchmahlGEMHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinomaInt J Cancer200410926527314750179
   PubMed Web of Science ®Google Scholar
• PengWChenJQLiuCLoss of PTEN promotes resistance to T cell-mediated immunotherapyCancer Discov2016620221626645196
   PubMed Web of Science ®Google Scholar
• SprangerSBaoRGajewskiTFMelanoma-intrinsic beta-catenin signalling prevents anti-tumour immunityNature201552323123525970248
   PubMed Web of Science ®Google Scholar
• FerrucciPFAsciertoPAPigozzoJBaseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumabAnn Oncol20162773273826802161
   PubMed Web of Science ®Google Scholar
• LinGLiuYLiSElevated neutrophil-to-lymphocyte ratio is an independent poor prognostic factor in patients with intrahepatic cholangiocarcinomaOncotarget20167509635097126918355
   PubMedGoogle Scholar
• MartensAWistuba-HamprechtKGeukes FoppenMBaseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumabClin Cancer Res2016222908291826787752
   PubMed Web of Science ®Google Scholar
• WeideBMartensAHasselJCBaseline biomarkers for outcome of melanoma patients treated with pembrolizumabClin Cancer Res2016225487549627185375
   PubMed Web of Science ®Google Scholar
• ZaragozaJCailleABenetonNHigh neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanomaBr J Dermatol201617414615126343230
   PubMed Web of Science ®Google Scholar
• JeyakumarGKimSBummaNNeutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapyJ Immunother Cancer201758229041991
   PubMed Web of Science ®Google Scholar
• LalaniAAXieWMartiniDJChange in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinomaJ Immunother Cancer20186529353553
   PubMed Web of Science ®Google Scholar
• RosnerSKwongEShoushtariANPeripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanomaCancer Med2018769069729468834
   PubMed Web of Science ®Google Scholar
• SunRChampiatSDercleLBaseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors)Eur J Cancer20178420221128826073
   PubMed Web of Science ®Google Scholar
• SubrahmanyamPBDongZGusenleitnerDDistinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patientsJ Immunother Cancer201861829510697
   PubMed Web of Science ®Google Scholar
• KriegCNowickaMGugliettaSHigh-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapyNat Med20182414415329309059
   PubMed Web of Science ®Google Scholar
• MeyerCCagnonLCosta-NunesCMFrequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumabCancer Immunol Immunother20146324725724357148
   PubMed Web of Science ®Google Scholar
• ChaEKlingerMHouYImproved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patientsSci Transl Med20146238ra270
   Web of Science ®Google Scholar
• McNeelDGTCR diversity – a universal cancer immunotherapy biomarker?J Immunother Cancer201646927879971
   PubMed Web of Science ®Google Scholar
• RobertLTsoiJWangXCTLA4 blockade broadens the peripheral T-cell receptor repertoireClin Cancer Res2014202424243224583799
   PubMed Web of Science ®Google Scholar
• HuangACPostowMAOrlowskiRJT-cell invigoration to tumour burden ratio associated with anti-PD-1 responseNature2017545606528397821
   PubMed Web of Science ®Google Scholar
• QueiroloPMorabitoALaurentSAssociation of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot studyCancer Invest20133133634523641913
   PubMed Web of Science ®Google Scholar
• BreunisWBTarazona-SantosEChenRKileyMRosenbergSAChanockSJInfluence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockadeJ Immunother20083158659018528295
   PubMed Web of Science ®Google Scholar
• VetizouMPittJMDaillereRAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiotaScience20153501079108426541610
   PubMed Web of Science ®Google Scholar
• SivanACorralesLHubertNCommensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacyScience20153501084108926541606
   PubMed Web of Science ®Google Scholar
• RoutyBLe ChatelierEDerosaLGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumorsScience2018359919729097494
   PubMed Web of Science ®Google Scholar
• MatsonVFesslerJBaoRThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patientsScience201835910410829302014
   PubMed Web of Science ®Google Scholar
• ChaputNLepagePCoutzacCCarbonnel, baseline gut micro-biota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumabAnn Oncol2017281368137928368458
   PubMed Web of Science ®Google Scholar
• BlankCUHaanenJBRibasASchumacherTNCANCER IMMUNOLOGY. The “cancer immunogram”Science201635265866027151852
   PubMed Web of Science ®Google Scholar